Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
23 hedge funds and large institutions have $5.39M invested in Carisma Therapeutics in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 3 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
179% more capital invested
Capital invested by funds: $1.93M → $5.39M (+$3.46M)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
5% more funds holding
Funds holding: 22 → 23 (+1)
0.8% more ownership
Funds ownership: 0.25% → 1.04% (+0.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$361K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$133K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$60.6K |
| 4 |
Parallax Volatility Advisers
San Francisco,
California
|
+$34.2K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
+$15.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$83K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$15.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$6.84K |
| 4 |
AG
Advisor Group
Phoenix,
Arizona
|
-$2K |
CARM Hedge Fund Activity: Q4 2017 in Review
23 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q4 2017, worth a combined $5.39M — up 179% from $1.93M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CARM positions and 3 closed out — a net gain of 1 holder — while 7 added to existing stakes and 2 trimmed.
The largest buyer was Virtu Financial, adding an estimated $361K. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $83K sold.
- 23 institutional investors held Carisma Therapeutics (CARM) as of Q4 2017, up from 22 in Q3 2017.
- Funds reported $5.39M of Carisma Therapeutics stock for Q4 2017, up 179% quarter-over-quarter.
- 4 funds opened new Carisma Therapeutics positions in Q4 2017 and 3 closed out, a net change of +1 holder.
- The largest Carisma Therapeutics buyer in Q4 2017 was Virtu Financial, an estimated $361K added.
- The largest Carisma Therapeutics seller in Q4 2017 was T. Rowe Price Associates, an estimated $83K sold.
Based on aggregated 13F filings for Q4 2017.